A Phase 3 interventional study of Technosphere® Insulin and Technosphere Powder in Type 2 Diabetes, sponsored by Mannkind Corporation. Completed at 76 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-10-17.
Sponsored by Mannkind Corporation · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 49 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 2 — none open to participants now, 1 under way, none of them phase 3. Insulin, Regular, Human · Diabetes Mellitus, Type 2.
Among the 49 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 2, this one is the 14th largest by enrollment, is one of 3 that started in 2011, is one of 25 in phase 3, and was the 35th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →None of the 49 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →
Insulin, Regular, Human: first FDA approval 1982 (HUMULIN R PEN), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
49 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 9 · Phase 3 26 · Phase 4 7
First in 1999; this study’s year is marked. 3 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 353 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 129 across the 49 interventional studies. Of the 46 that completed or were terminated, 11 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
37 of 49 have an industry lead sponsor. The 10 most frequent:
Mannkind Corporation is the lead sponsor of 57 studies on the registry; 3 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 3 (38%) have results posted.
23 studies in Diabetes Mellitus, Type 2 by Mannkind Corporation: none open now, none under way, none of them phase 3. Of 22 finished, 10 (45%) have results posted.
Among the 23 studies in Diabetes Mellitus, Type 2 by Mannkind Corporation, this one is the 4th largest by enrollment of the 20 interventional ones that give a count, is the only one that started in 2011, is one of 9 in phase 3, and was the 20th registered.
Mannkind Corporation’s Diabetes Mellitus, Type 2 studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 49 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Mannkind Corporation’s 23 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Insulin-naive subjects with Type 2 Diabetes Mellitus who are sub-optimally controlled on either maximum tolerated dose of metformin or maximum tolerated dose of metformin plus one or two other oral anti-diabetic medications will have either Prandial Technosphere® Insulin or Technosphere Powder (placebo) added to their oral antidiabetic drugs.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Currently receiving as diabetes treatment only metformin or 2 or more OADs and on stable doses for at least 3 months before enrollment
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Technosphere® Insulin powder administered via the Gen2 inhaler added to 2 or more stable OADs
Drug: Technosphere® Insulin
Technosphere powder (with no insulin) administered via the Gen2 inhaler added to 2 or more stable OADs
Drug: Technosphere Powder
Technosphere® Insulin Inhalation Powder
Placebo Comparator
Change From Baseline to Week 24 in HbA1c
Efficacy as measured by change in glycated hemoglobin (HbA1c) at Week 24
Time frame: Baseline to Week 24
Proportion of Responders Achieving HbA1c <= 7.0%
Efficacy as measured in proportion of subjects achieving HbA1c \< or = to 7.0%
Time frame: Week 24
Proportion of Responders Achieving HbA1c <= 6.5%
Efficacy as measured in proportion of subjects achieving HbA1c \< or = to 6.5% at Week 24
Time frame: Week 24
FPG Change From Baseline to Week 24
Efficacy as measured by mean change in fasting plasma glucose (FPG)
Time frame: Baseline to Week 24
Proportion of Subjects Requiring Rescue Therapy
Time frame: Baseline to Week 24
Time to Rescue
Time from Week 0 (baseline) to initiation of rescue therapy (up to a maximum of 24 weeks/end of treatment) for subjects not responding to treatment
Time frame: Baseline to Week 24
FEV1 Change From Baseline to Week 24
Forced Expiratory Volume in 1 second - change from baseline to week 24
Time frame: Baseline to Week 24
Incidence of Total Hypoglycemia
Hypoglycemia, defined as blood glucose \<= 70 mg/dL or in absence of blood glucose, symptoms that are resolved by the administration of carbohydrates.
Time frame: Baseline to Week 24
Incidence of Severe Hypoglycemia
Severe Hypoglycemia defined as: Requiring 3rd party assistance.
Time frame: Baseline to Week 24
Total Hypoglycemia Event Rate
Number of Hypoglycemic Events/Total Subject Exposure Time (in months)
Time frame: Baseline to Week 24
Severe Hypoglycemia Event Rate
Number of Severe Hypoglycemic Events/Total Subject Exposure Time (in months)
Time frame: Baseline to Week 24
Mean 7-point Glucose Baseline Values
Mean 7-point self-monitored glucose at baseline
Time frame: Baseline
Mean 7-point Glucose Week 24 Values
Mean 7-point self-monitored blood glucose at Week 24
Time frame: Week 24
Change in Body Weight From Baseline to Week 24
Change in body weight from Baseline to Week 24
Time frame: Baseline to Week 24
First Patient enrolled November 2011. Multi-national trial conducted in US, Russia, Ukraine and Brazil
| Milestone | TI Inhalation Powder + OADs | Technosphere Powder |
|---|---|---|
| Started | 177 | 176 |
| Completed | 150 | 139 |
| Not completed | 27 | 37 |
| Withdrew: Adverse event | 7 | 9 |
| Withdrew: Protocol violation | 1 | 2 |
| Withdrew: Physician decision | 1 | 1 |
| Withdrew: Withdrawal by subject | 10 | 14 |
| Withdrew: Lost to follow-up | 6 | 4 |
| Withdrew: Non-compliance with study drug | 1 | 3 |
| Withdrew: Non-compliance with protocol | 1 | 1 |
| Withdrew: Moved out of country | 0 | 1 |
| Withdrew: Adverse event + elevated fasting glucose | 0 | 1 |
| Withdrew: Lack of efficacy | 0 | 1 |
Efficacy as measured by change in glycated hemoglobin (HbA1c) at Week 24
| percentage of hemoglobin | TI Inhalation Powder + OADs | Technosphere Powder |
|---|---|---|
| Change From Baseline to Week 24 in HbA1c | -0.82 ± 0.061 | -0.42 ± 0.062 |
Efficacy as measured in proportion of subjects achieving HbA1c \< or = to 7.0%
| percentage of participants | TI Inhalation Powder + OADs | Technosphere Powder |
|---|---|---|
| Proportion of Responders Achieving HbA1c <= 7.0% | 37.7 | 19.0 |
Efficacy as measured in proportion of subjects achieving HbA1c \< or = to 6.5% at Week 24
| percentage of participants | TI Inhalation Powder + OADs | Technosphere Powder |
|---|---|---|
| Proportion of Responders Achieving HbA1c <= 6.5% | 15.9 | 4.2 |
Efficacy as measured by mean change in fasting plasma glucose (FPG)
| mg/dL | TI Inhalation Powder + OADs | Technosphere Powder |
|---|---|---|
| FPG Change From Baseline to Week 24 | -11.20 ± 3.776 | -3.78 ± 3.864 |
| percentage of participants | TI Inhalation Powder + OADs | Technosphere Powder |
|---|---|---|
| Proportion of Subjects Requiring Rescue Therapy | 6.8 | 9.7 |
Time from Week 0 (baseline) to initiation of rescue therapy (up to a maximum of 24 weeks/end of treatment) for subjects not responding to treatment
| Days | TI Inhalation Powder + OADs | Technosphere Powder |
|---|---|---|
| Time to Rescue | 95 (22 to 141) | 85 (28 to 160) |
Forced Expiratory Volume in 1 second - change from baseline to week 24
| Liters | TI Inhalation Powder + OADs | Technosphere Powder |
|---|---|---|
| FEV1 Change From Baseline to Week 24 | -0.13 ± 0.175 | -0.04 ± 0.147 |
Hypoglycemia, defined as blood glucose \<= 70 mg/dL or in absence of blood glucose, symptoms that are resolved by the administration of carbohydrates.
| percentage of participants | TI Inhalation Powder + OADs | Technosphere Powder |
|---|---|---|
| Incidence of Total Hypoglycemia | 67.8 | 30.7 |
Severe Hypoglycemia defined as: Requiring 3rd party assistance.
| percentage of participants | TI Inhalation Powder + OADs | Technosphere Powder |
|---|---|---|
| Incidence of Severe Hypoglycemia | 5.1 | 1.7 |
Number of Hypoglycemic Events/Total Subject Exposure Time (in months)
| Events/Subject-Month | TI Inhalation Powder + OADs | Technosphere Powder |
|---|---|---|
| Total Hypoglycemia Event Rate | 1.16 | 0.50 |
Number of Severe Hypoglycemic Events/Total Subject Exposure Time (in months)
| Events/100 Subject-Month | TI Inhalation Powder + OADs | Technosphere Powder |
|---|---|---|
| Severe Hypoglycemia Event Rate | 2.37 | 0.60 |
Mean 7-point self-monitored glucose at baseline
| mg/dL | TI Inhalation Powder + OADs | Technosphere Powder |
|---|---|---|
| Before Breakfast | 178.5 ± 37.58 | 182.2 ± 40.50 |
| After Breakfast | 212.8 ± 51.01 | 219.9 ± 51.77 |
| Before Lunch | 176.7 ± 49.58 | 183.6 ± 53.76 |
| After Lunch | 197.0 ± 46.94 | 209.1 ± 44.37 |
| Before Dinner | 176.8 ± 41.81 | 187.6 ± 50.04 |
| After Dinner | 205.2 ± 48.72 | 211.2 ± 50.44 |
| Bedtime | 203.3 ± 50.55 | 203.8 ± 46.52 |
Mean 7-point self-monitored blood glucose at Week 24
| mg/dL | TI Inhalation Powder + OADs | Technosphere Powder |
|---|---|---|
| Before Breakfast | 156.6 ± 30.80 | 160.9 ± 36.7 |
| After Breakfast | 170.3 ± 44.23 | 194.7 ± 50.02 |
| Before Lunch | 152.4 ± 48.13 | 163.4 ± 49.8 |
| After Lunch | 158.0 ± 42.79 | 183.8 ± 47.73 |
| Before Dinner | 157.4 ± 49.34 | 164.7 ± 40.60 |
| After Dinner | 164.3 ± 44.84 | 188.5 ± 43.93 |
| Bedtime | 163.0 ± 42.66 | 178.7 ± 44.50 |
Change in body weight from Baseline to Week 24
| kg | TI Inhalation Powder + OADs | Technosphere Powder |
|---|---|---|
| Change in Body Weight From Baseline to Week 24 | 0.49 ± 0.333 | -1.13 ± 0.347 |
Collected over 24 Weeks. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| TI Inhalation Powder | — | 5/177 (2.8%) | 108/177 (61%) |
| Technosphere Powder | — | 9/176 (5.1%) | 82/176 (46.6%) |
| Event | TI Inhalation Powder | Technosphere Powder |
|---|---|---|
| Myocardial InfarctionCardiac disorders | 2/177 | 0/176 |
| Angina PectorisCardiac disorders | 0/177 | 1/176 |
| Coronary Artery DiseaseCardiac disorders | 0/177 | 1/176 |
| CyanosisCardiac disorders | 0/177 | 1/176 |
| Skull MalformationCongenital, familial and genetic disorders | 0/177 | 1/176 |
| Humerus FractureInjury, poisoning and procedural complications | 0/177 | 1/176 |
| Heart Rate DecreasedInvestigations | 0/177 | 1/176 |
| Back PainMusculoskeletal and connective tissue disorders | 0/177 | 1/176 |
| Squamous Cell CarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/177 | 1/176 |
| Ischemic StrokeNervous system disorders | 0/177 | 1/176 |
| Event | TI Inhalation Powder | Technosphere Powder |
|---|---|---|
| CoughRespiratory, thoracic and mediastinal disorders | 42/177 | 35/176 |
| NasopharyngitisInfections and infestations | 15/177 | 8/176 |
| InfluenzaInfections and infestations | 10/177 | 3/176 |
| Upper Respiratory Tract InfectionInfections and infestations | 9/177 | 5/176 |
| Oropharyngeal PainRespiratory, thoracic and mediastinal disorders | 8/177 | 4/176 |
| BronchitisInfections and infestations | 5/177 | 7/176 |
| HeadacheNervous system disorders | 7/177 | 5/176 |
| DiarrhoeaGastrointestinal disorders | 6/177 | 3/176 |
| Urinary Tract InfectionInfections and infestations | 6/177 | 2/176 |
| Respiratory Tract Infection ViralInfections and infestations | 2/177 | 5/176 |
Safety population
| Age, Customized(participants) | TI Inhalation Powder + OADs | Technosphere Powder | Total |
|---|---|---|---|
| 18-30 years | 1 | 0 | 1 |
| 31-49 years | 37 | 33 | 70 |
| 50-64 years | 102 | 110 | 212 |
| >=65 years | 37 | 33 | 70 |
| Sex: Female, Male(Participants) | TI Inhalation Powder + OADs | Technosphere Powder | Total |
|---|---|---|---|
| Female | 95 | 102 | 197 |
| Male | 82 | 74 | 156 |
| Race (NIH/OMB)(Participants) | TI Inhalation Powder + OADs | Technosphere Powder | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 1 | 2 |
| Asian | 1 | 2 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 21 | 17 | 38 |
| White | 151 | 155 | 306 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 3 | 1 | 4 |
| Ethnicity (NIH/OMB)(Participants) | TI Inhalation Powder + OADs | Technosphere Powder | Total |
|---|---|---|---|
| Hispanic or Latino | 43 | 41 | 84 |
| Not Hispanic or Latino | 134 | 135 | 269 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | TI Inhalation Powder + OADs | Technosphere Powder | Total |
|---|---|---|---|
| United States | 88 | 87 | 175 |
| Brazil | 15 | 14 | 29 |
| Ukraine | 19 | 19 | 38 |
| Russian Federation | 55 | 56 | 111 |
| Duration of Diabetes(years) | TI Inhalation Powder + OADs | Technosphere Powder | Total |
|---|---|---|---|
| Mean | 9.7 (1.1 to 34.7) | 9.2 (1.0 to 28.8) | 9.5 (1.0 to 34.7) |
| Weight(kg) | TI Inhalation Powder + OADs | Technosphere Powder | Total |
|---|---|---|---|
| Mean | 90.2 (54.0 to 142.3) | 90.8 (58.0 to 136.6) | 90.5 (54.0 to 142.3) |
| BMI(kg/m^2) | TI Inhalation Powder + OADs | Technosphere Powder | Total |
|---|---|---|---|
| Mean | 31.8 (21.6 to 44.6) | 32.4 (21.1 to 44.4) | 32.1 (21.1 to 44.6) |
3 further baseline measures are reported on the registry.
The record gives a start of Nov 2011, a primary completion of Jun 2013 and a completion of Jul 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2014, 1 year 4 months after primary completion. A results delay was requested in Aug 2013.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Insulin, Regular, Human